We are pleased to inform that the Company has received a Certificate of Suitability (CEP) from the European Directorate for the Quality of Medicines & Helathcare (EDQM), Europe for its ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Smruthi Organics has received a Certificate of Suitability (CEP) from the European Directorate for the Quality of Medicines & HealthCare (EDQM) for its product Amlodipine Besilate, a widely used blood pressure medication ingredient. The CEP confirms that the product meets the quality standards of the European Pharmacopoeia. With this certification, the company can now supply Amlodipine Besilate to pharmaceutical manufacturers in European markets and other regions that recognize CEP certification. This adds to the company's regulatory portfolio and opens doors to business in regulated, high-value markets.
Positive for shareholders — CEP approval enables entry into European and other regulated markets, potentially driving new export revenue and strengthening the company's long-term growth prospects. No immediate financial figures have been disclosed.